Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ohtuvayre
Pharma
Merck reports mixed results in Q1 for Winrevair, Ohtuvayre
While Merck's Winrevair continued its upward trajectory, another of its growth products, Ohtuvayre, took a step back in the first quarter.
Kevin Dunleavy
Apr 30, 2026 11:40am
Merck had no other competition in its $10B buyout of Verona
Aug 7, 2025 7:00am
Merck pays $10B to acquire Verona and COPD drug Ohtuvayre
Jul 9, 2025 11:25am
Breaking down the 55 new drug approvals of 2024
Jan 10, 2025 9:00am
